Radiopharm Theranostics (ASX:RAD) Total Stockholders Equity : A$24.23 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Total Stockholders Equity?

Radiopharm Theranostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$24.23 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Radiopharm Theranostics's Book Value per Share for the quarter that ended in Dec. 2023 was A$0.07. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Radiopharm Theranostics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.00.

Radiopharm Theranostics Total Stockholders Equity Historical Data

The historical data trend for Radiopharm Theranostics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Total Stockholders Equity Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Total Stockholders Equity

62.96

44.38

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	73.42	62.96	61.87	44.38	24.23

Radiopharm Theranostics (ASX:RAD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Radiopharm Theranostics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(24.234	-	0)	/	371.639
	=	0.07

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Radiopharm Theranostics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	24.234
	=	0.00

Radiopharm Theranostics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (ASX:RAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RDPTF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines